Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Somatic epidermal growth factor receptor (EGFR) mutations are present in around 50% of Asian patients and in 10–15% of Caucasian patients with metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The first-generation EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotini...

Full description

Bibliographic Details
Main Authors:	Sami Morin-Ben Abdallah, Vera Hirsh
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-05-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor afatinib gefitinib erlotinib
Online Access:	http://journal.frontiersin.org/article/10.3389/fonc.2017.00097/full

Similar Items

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
by: Ming-Ju Tsai, et al.
Published: (2018-11-01)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
by: O.M. Smorodska, et al.
Published: (2021-06-01)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
by: Sheng-Kai Liang, et al.
Published: (2021-01-01)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021-08-01)

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
by: Duan H, et al.
Published: (2018-04-01)

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
by: Yang CJ, et al.
Published: (2016-03-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
by: Holleman MS, et al.
Published: (2019-02-01)

Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
by: Qian J, et al.
Published: (2020-05-01)

TKI Resistance for T790M Mutation
by: Hong WANG, et al.
Published: (2015-04-01)

Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
by: Barbara eMelosky
Published: (2014-09-01)

Retreatment with Epidermal Growth Factor Receptor Inhibitor After Initial Failure in Advanced Non-small Cell Lung Cancer
by: Tongtong AN, et al.
Published: (2011-03-01)

The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
by: V V Ryazhenov
Published: (2017-01-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
by: Marc-Eric Halatsch, et al.
Published: (2012-05-01)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
by: Wu JY, et al.
Published: (2016-10-01)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
by: Yi-Chieh Chen, et al.
Published: (2021-05-01)

Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
by: Hong TAO, et al.
Published: (2014-04-01)

“Liquid elbows” due to afatinib administration
by: Paul Zarogoulidis, et al.
Published: (2017-01-01)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01)

Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
by: Aliyah Almomen, et al.
Published: (2020-09-01)

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report
by: Frank S. Fan
Published: (2016-09-01)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Gwo-Fuang Ho, et al.
Published: (2019-09-01)

Tyrosine Kinase Inhibitors in EGFR-Mutated Large-Cell Neuroendocrine Carcinoma of the Lung A Case Report
by: Francesca Aroldi, et al.
Published: (2014-07-01)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
by: Chih-Jen Yang, et al.
Published: (2017-12-01)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
by: Murray Samuel, et al.
Published: (2012-09-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
by: Paul Zarogoulidis, et al.
Published: (2017-01-01)

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation
by: Patel N, et al.
Published: (2017-06-01)

Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future
by: Chancellor E. Donald, et al.
Published: (2011-12-01)

Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
by: Xu Y, et al.
Published: (2016-05-01)

Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations
by: Naoto Aiko, et al.
Published: (2018-10-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
by: Toshiyuki Sumi, et al.
Published: (2021-07-01)

Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report
by: Tomoki Tamura, et al.
Published: (2021-06-01)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
by: Yuko Oya, et al.
Published: (2021-01-01)

Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
by: Laksmi Wulandari, et al.
Published: (2018-07-01)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
by: Chih-Jen Yang, et al.
Published: (2017-05-01)